Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tor Magnus Smedman"'
Autor:
Trygve Syversveen, Harald Grut, Tor Magnus Smedman, Pål-Dag Line, Lars H. Jørgensen, Svein Dueland, Bård I. Røsok
Publikováno v:
Transplant International. 34:2205-2213
Liver transplantation (LT) in selected colorectal cancer (CRC) patients with nonresectable liver-only metastases may result in 5-year overall survival of up to about 70-100%. However, the majority will have recurrent disease. All patients included in
Autor:
Svein Dueland, Tor Magnus Smedman, Harald Grut, Trygve Syversveen, Lars Hilmar Jørgensen, Pål-Dag Line
Publikováno v:
Cancers; Volume 14; Issue 20; Pages: 5042
The objective of the study was to determine the impact of PET uptake on liver metastases on overall survival (OS) after resection of pulmonary metastases in patients who had received liver transplantation (LT) due to unresectable colorectal liver-onl
Autor:
Tor Magnus Smedman, Tormod Kyrre Guren, Kjell Magne Tveit, Maria Thomsen, Marit Helen Andersen, Pål-Dag Line, Svein Dueland
Publikováno v:
Transplant International. 35
Liver transplantation (LT) for patients with non-resectable colorectal liver metastases (CRLM) offers improved survival and has gained increased interest internationally the last years. The aim of this study was to describe the health-related quality
Autor:
Morten Hagness, Pål-Dag Line, Harald Grut, Trygve Syversveen, Tor Magnus Smedman, Svein Dueland
Publikováno v:
BJS Open
BJS Open, Vol 4, Iss 3, Pp 467-477 (2020)
BJS Open, Vol 4, Iss 3, Pp 467-477 (2020)
Background Patients with metastatic colorectal cancer receiving palliative chemotherapy have a 5‐year survival rate of approximately 10 per cent. Liver transplantation using strict selection criteria in patients with colorectal cancer and unresecta
Solid organ recipients have a 2-5 fold increased risk of malignancy compared to the general population. Because of the broader indications for transplantation, it is anticipated that an increasing number of organ graft recipients will present with ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b4dd5b6a3254c3a7c0a2c7d08b6daa3
http://hdl.handle.net/10852/74917
http://hdl.handle.net/10852/74917
Publikováno v:
Acta oncologica (Stockholm, Sweden). 57(10)
Immune checkpoint therapy, targeting regulatory pathways in T cells, has led to important clinical advances and improved outcomes in patients with malignant diseases [1]. Ipilimumab, a monoclonal h...